This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through July 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
medical-devices: Archive
Reasons to Hold AngioDynamics Stock in Your Portfolio for Now
by Zacks Equity Research
ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.
medical medical-devices
HIMS vs. TDOC: Which Telehealth Stock Looks More Compelling?
by Debanjana Dey
Hims & Hers and Teladoc Health are expanding virtual care in different ways, but which telehealth platform looks more compelling right now? Let's dive in.
medical medical-devices
Should You Buy Midland States Bancorp (MSBI) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy X4 Pharmaceuticals (XFOR) After Golden Cross?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
by Moumi Mondal
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
medical medical-devices
Is Quest Diagnostics Stock a Right Pick for Your Portfolio Now?
by Zacks Equity Research
DGX banks on acquisitions, advanced diagnostics and cost discipline, even as debt levels and macro pressures pose risks.
medical medical-devices
Intuitive Surgical vs. Stryker: Which MedTech Stock Has More Upside?
by Indrajit Bandyopadhyay
Intuitive Surgical's robotics-first model, recurring revenue base, and margin leverage differentiate it from Stryker in terms of upside potential today.
medical medical-devices
Here's Why You Should Retain Merit Medical Stock in Your Portfolio Now
by Zacks Equity Research
Merit Medical shows resilience despite 2025 share pressure, supported by cardiovascular growth, margin expansion and WRAPSODY CIE momentum.
medical medical-devices
3 Healthcare IT Stocks Up More Than 20% in 2025 With More Room to Run
by Indrajit Bandyopadhyay
Three Healthcare IT stocks have surged over 20% in 2025, driven by growth in telehealth, remote monitoring and value-based care platforms.
medical medical-devices
FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform
by Zacks Equity Research
Fulgent is set to buy Bako Diagnostics assets and StrataDx for $55.5M, expanding into anatomic pathology and dermatopathology to scale lab services.
medical medical-devices